Ironwood Pharma (IRWD) Misses Q1 EPS by 1c; Offers FY23 Revenue Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of $0.25, $0.01 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $104.06 million versus the consensus estimate of $100.3 million.

GUIDANCE:

Ironwood Pharma sees FY2023 revenue of $420-435 million, versus the consensus of $426.4 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance